CrEDIT: Digital CBT-I for Insomnia Disorder

Sponsor
Big Health Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05541055
Collaborator
University of California, San Francisco (Other)
332
1
2
12
27.7

Study Details

Study Description

Brief Summary

This study will examine the effectiveness of digital CBT-I versus sleep hygiene education in reducing insomnia severity, sleep onset latency, and wake after sleep onset in those with insomnia disorder.

Condition or Disease Intervention/Treatment Phase
  • Device: digital CBT-I
  • Other: Sleep hygiene education
N/A

Detailed Description

This study aims to examine the effectiveness of a fully-automated web and app-based digital CBT-I for insomnia compared to sleep hygiene education (SHE) in individuals with a diagnosis of insomnia disorder. Primary outcomes of interest include changes in insomnia severity, sleep onset latency, and wake after sleep onset throughout the course of the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
332 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Effectiveness of Digital CBT-I for the Treatment of Insomnia Disorder: A Randomized Controlled Trial
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Digital CBT-I

Digitally-delivered CBT for insomnia accessed via web and/or mobile app

Device: digital CBT-I
A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.

Active Comparator: Sleep hygiene education

This group will receive access to sleep hygiene education delivered via digital written materials

Other: Sleep hygiene education
Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.

Outcome Measures

Primary Outcome Measures

  1. Change in the Insomnia Severity Index (ISI) [From baseline to 10 weeks post-randomization]

    Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity

  2. Change in sleep onset latency (SOL) [From baseline to 10 weeks post-randomization]

    Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days

  3. Change in wake after sleep onset (WASO) [From baseline to 10 weeks post-randomization]

    Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days

Secondary Outcome Measures

  1. Insomnia Disorder remission (score <8) and response (change ≥6) on the ISI [10, 16, and 24 weeks post-randomization]

    Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity

  2. Insomnia disorder remission based on the SCID Insomnia Module [Week -1 compared to weeks 10, 16, and 24 post-randomization]

    structured interview to assess for Insomnia Disorder

  3. Change in sleep diary parameters: percent sleep efficiency (SE), total sleep time (TST), total time in bed (TTIB), and total wake time (TWT) [From lead-in period to 10, 16, and 24 weeks post-randomization]

    Each measured in minutes by daily sleep diaries (based on the Consensus Sleep Diary)

  4. Change in the Sleep Condition Indicator (SCI-8) [From baseline to weeks 10, 16, and 24 post-randomization]

    Validated questionnaire; an 8-item scale with total scores between 0 and 32 where higher scores indicate better sleep

  5. Change in the Generalized Anxiety Disorder Questionnaire (GAD-7) [From baseline to weeks 10, 16, and 24 post-randomization]

    Validated questionnaire; a 7-item scale with total scores between 0 and 21 where higher scores indicate greater severity

  6. Change in the Patient Health Questionnaire (PHQ-8) [From baseline to weeks 10, 16 and 24 post-randomization]

    Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity

  7. Change in the Insomnia Severity Index (ISI) [From baseline to weeks 16 and 24 post-randomization]

    Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity

  8. Change in sleep onset latency (SOL) [From baseline to weeks 16 and 24 post-randomization]

    Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days

  9. Change in wake after sleep onset (WASO) [From baseline to weeks 16 and 24 post-randomization]

    Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age ≥22 years old

  • Insomnia Disorder diagnosis Score ≤16 on the 8-item Sleep Condition Indicator

  • 30 minutes sleep onset latency (SOL); and/or > 30 minutes wake after sleep onset (WASO)

  • Current resident of the USA

  • Oral and written fluency in English

  • Participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form

Exclusion Criteria:
  • Must not be currently receiving or be expecting to start CBT for insomnia during study participation, or have previously received CBT for insomnia in the past 12-months (self-report)

  • If on psychoactive medication, including sleep medication, this must be stable for at least 5 half lives

  • Past or present psychosis, schizophrenia, bipolar disorder, assessed by self-report and/or seizure disorder

  • Occupation that requires alertness / caution to avoid accidents, for example long-haul driving, long distance bus driver, heavy machinery operator, air traffic controller

  • Hearing or vision impairment that prevents effective use of the audio-visual content of digital CBT-I or SHE in the opinion of the investigator

  • Intellectual disability or any Neurocognitive or Neurodevelopmental disorder that would prevent participants from following study procedures

  • Any condition that the investigator believes would make participation in the study not in the best interest of the participant or would preclude successful completion of study activities

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, San Francisco San Francisco California United States 94143

Sponsors and Collaborators

  • Big Health Inc.
  • University of California, San Francisco

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Big Health Inc.
ClinicalTrials.gov Identifier:
NCT05541055
Other Study ID Numbers:
  • BH-S-01
First Posted:
Sep 15, 2022
Last Update Posted:
Sep 15, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Big Health Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2022